Modulation of inflammatory mediators and pparγand nfκb expression by pravastatin in response to lipoproteins in human monocytes in vitro
- 28 February 2002
- journal article
- Published by Elsevier in Pharmacological Research
- Vol. 45 (2) , 147-154
- https://doi.org/10.1006/phrs.2001.0922
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cellsLife Sciences, 2000
- Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cellsAtherosclerosis, 1999
- Statins and Blockers of the Renin-Angiotensin SystemHypertension, 1999
- Non‐lipid properties of statinsJournal of Clinical Pharmacy & Therapeutics, 1999
- Reduction of Serum Cholesterol Levels Alters Lesional Composition of Atherosclerotic PlaquesArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluationAtherosclerosis, 1994
- Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions.Journal of Clinical Investigation, 1994
- Toxicity of a Novel HMG-CoA Reductase Inhibitor in the Common Marmoset (Callithrix jacchus)Human & Experimental Toxicology, 1994
- Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitorBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1990
- Clofibrate Reversal of Platelet Hypersensitivity in HyperbetalipoproteinemiaCirculation, 1974